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j ourna l homepage: www.e lsev ie r .com/ locate /bbad isPrefaceSpecial issue: Molecular basis of NCLThe neuronal ceroid lipofuscinoses (NCLs), also known as Batten dis-
ease, are a group of rare and devastating neurodegenerative disorders.
They are genetic diseases, usually inherited in an autosomal recessive
manner, and at present are incurable. Disease can present at any age,
from before birth up to late in life, although those most affected are
children.
An international meeting on the NCLs—the 14th international con-
ference, NCL2014 (http://www.nclcordoba.com) together with the
2nd international patients organisation meeting—was held in October
2014 in Córdoba, Argentina, the ﬁrst such international meeting on
the NCLs in Latin America. It was organised by Prof Dr. Inés Noher de
Halac and colleagues. It was attended by a total of 116 clinical, scientiﬁc
and professional experts from around the world. There were 60 talks
and 41 posters. Following the meeting there was an additional day
spent at the National University Cordoba with further academic presen-
tations on the NCLs and a special workshop.In addition to these scientiﬁc and clinical activities, the parallel Fam-
ily Conference was hosted by the UK Batten Disease Family Association
and the USA Batten Disease and Support Research Association. This was
attended by 14 families and representatives from 4 organisations, and
gave families from Argentina in particular their ﬁrst chance to meet to-
gether. Some sessions were separate, but others were held jointly with
the scientiﬁc conference. These included an interactive ‘Market Place’
event that shared the wide expertise of all of those present and a
‘Round Table’ to discuss research gaps and how these could be ﬁlled.
This integration of science, clinical, professional and lay perspectives ex-
tended this progressive format initiated at the last international meet-
ing, and will continue in future scientiﬁc congresses in this ﬁeld.
This special issue allowed us to request a series of reviews from at-
tending experts. The aim of these reviews is to provide a broad rangehttp://dx.doi.org/10.1016/j.bbadis.2015.06.023
0925-4439/© 2015 Elsevier B.V. All rights reserved.of articles that summarise the current status of some aspects of the
NCL ﬁeld. They are not meant to be comprehensive, but it is hoped
that they will be useful to those new to this disease as well as those
long familiar with the NCLs. Shared co-authorship across different insti-
tutions for some of these reﬂects the excellent cooperative international
expertise that exists in research into this rare disease.
We can read about the translational research experience in
Argentina over more than a decade, covering hundreds of patients
(Kohan et al.). Cismondi leads an international authorship and presents
guidelines for incorporating scientiﬁc knowledge and practice on rare
diseases such as theNCLs into higher education and continuous learning
programmes that were suggested at the post-Congress workshop, with
a special perspective within Latin America.
Rare diseases are those with a particularly low prevalence; in
Europe, diseases are considered to be rare when they affect not more
than 5 in 10,000 persons in the European Union, and fewer than
200,000 persons in the USA. Rodwell and Aymé present a perspective
on policies for rare diseases to improve patient care in Europe, taking
into account the signiﬁcant public health challenges such as the limited
number of patients and scarcity of knowledge and expertise. Over the
last 16 years, a political framework at the European level has provided
legislation that is progressively improving care for families with rare
diseases. Kohlschütter et al. draws on discussion in a workshop at
NCL2014 to provide an ethical perspective on providing artiﬁcial nutri-
tion in children with degenerative diseases, including a checklist that
summarises important considerations.
The current genetic basis of the NCLs is summarised by Mole and
Cotman, with at least 10 clear NCL genetic forms and a few further
atypical and rarer subtypes that span some very diverse disease
phenotypes. Links to the web-based NCL Mutation Databases are pro-
vided. Cárcel-Trullols presents a complementary perspective on the cur-
rent understanding of the cell biology of the NCLs. There remain
signiﬁcant gaps in knowledge that hamper therapeutic development.
The pathomorphology of the NCLs is summarised by Radke et al. All
share loss of nerve cells, particularly in the cerebral and cerebellar cor-
tices, and the formation of lipopigments that have distinct ultrastructur-
al patterns. Little is known about extracerebral pathology, and a
full description of neuropathology is awaited for the more recently
recognised forms of NCL, dependent on autopsy. Pathology can still be
important in establishing a diagnosis of NCL.
A review ofmodel systems used to understand theNCLs and to reach
new therapies is provided by Faller et al. The focus is on the advantages
of each individual model, describing some of the contributions that dif-
ferent models have made to our understanding of the broader disease
biology and highlighting new techniques and approaches relevant to
the study and potential treatment of the NCLs. The models used may
2236 Prefacebe generated by genetic engineering or arise naturally, and include sim-
ple unicellular organisms, small vertebrates such as zebraﬁsh andmice,
and large animals such as sheep and dogs. Technological advances now
allow newmodels that provide additional beneﬁts in the future, such as
pigs that share some common physiology.
Studies using suchmodels extend understanding of NCL pathogene-
sis (Cooper et al.), for example, evidence for the pathway-dependent
pathology and involvement of more brain regions, glial dysfunction,
and pathology beyond the brain. Palmer et al. provide a speciﬁc summa-
ry of studies using the sheep model, and a separate perspective on sub-
unit c of mitochondrial ATP synthase, the main protein storage material
in many of the NCLs
An up to date summary of experimental therapies and approaches
used in the development of effective treatments for the different NCLs,
including small molecule, enzyme replacement and gene therapies,
stem cells, and current clinical trials is provided by Neverman et al.
This area is expanding each year, and the families have a keen interest
in any progress.
Finally, Stehr and van der Putten, who work for one of the several
non-proﬁt organisations initiated by parents around the world that ﬁll
essential gaps in support and funding, provide a perspective on bridging
research gaps, summarising discussion by diverse stakeholders around
eight themes at the round table on this topic.
This special issue closes with a short future perspective. There re-
mainmany unanswered questions around the NCLs. Not least is wheth-
er these are a true grouping of diseases. Progress in the NCL ﬁeld will
continue to be reported at biennial international meetings, with the
next being the 15th International Conference on NCL and Patient Orga-
nisation Meeting planned for Boston, USA, in October 2016.
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